BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
BetterLife Pharma has announced favorable cardiac safety data for its drug candidate BETR-001, a non-hallucinogenic derivative of LSD. The company completed GLP in vitro studies showing minimal impact on the hERG channel, important for cardiac functioning. The results align with previous in vivo cardiac safety telemetry studies and complement findings on BETR-001's activity at the 5HT-2B receptor, where it acts as an antagonist rather than an agonist. This is significant as agonism at 5HT-2B receptor is associated with cardiac valvulopathy. These positive results bring the company closer to completing IND-enabling studies and initiating clinical trials.
BetterLife Pharma ha annunciato dati favorevoli sulla sicurezza cardiaca per il suo candidato farmaco BETR-001, un derivato non allucinogeno dell'LSD. L'azienda ha completato studi in vitro GLP mostrando un impatto minimo sul canale hERG, importante per la funzionalità cardiaca. I risultati sono in linea con precedenti studi di telemetria sulla sicurezza cardiaca in vivo e completano le scoperte sull'attività di BETR-001 al recettore 5HT-2B, dove agisce come antagonista piuttosto che come agonista. Questo è significativo poiché l'agonismo al recettore 5HT-2B è associato a valvulopatia cardiaca. Questi risultati positivi avvicinano l'azienda al completamento degli studi abilitanti IND e all'avvio delle sperimentazioni cliniche.
BetterLife Pharma ha anunciado datos favorables sobre la seguridad cardíaca de su candidato a medicamento BETR-001, un derivado no alucinógeno del LSD. La empresa completó estudios in vitro GLP que muestran un impacto mínimo en el canal hERG, importante para el funcionamiento cardíaco. Los resultados están alineados con estudios previos de telemetría de seguridad cardíaca in vivo y complementan los hallazgos sobre la actividad de BETR-001 en el receptor 5HT-2B, donde actúa como antagonista en lugar de agonista. Esto es significativo ya que el agonismo en el receptor 5HT-2B se asocia con valvulopatía cardíaca. Estos resultados positivos acercan a la empresa al final de los estudios habilitantes de IND y al inicio de ensayos clínicos.
BetterLife Pharma는 자사 약물 후보인 BETR-001의 유리한 심장 안전성 데이터를 발표했습니다. BETR-001은 LSD의 비환각성 유도체입니다. 이 회사는 심장 기능에 중요한 hERG 채널에 미치는 영향이 최소임을 보여주는 GLP 인 비트로 연구를 완료했습니다. 이 결과는 이전의 인 비보 심장 안전성 원거리 센서 연구와 일치하며, BETR-001이 5HT-2B 수용체에서 작용할 때 길항제로 작용한다는 발견과 보완 관계에 있습니다. 이는 5HT-2B 수용체에서의 길항제가 심장 판막병증과 관련이 있기 때문에 중요합니다. 이러한 긍정적인 결과는 회사를 IND 승인 연구 완료 및 임상 시험 시작에 더 가까이 가져다줍니다.
BetterLife Pharma a annoncé des données favorables sur la sécurité cardiaque de son candidat médicament BETR-001, un dérivé non hallucinogène du LSD. L'entreprise a complété des études in vitro GLP montrant un impact minimal sur le canal hERG, qui est important pour le fonctionnement cardiaque. Les résultats s'alignent avec des études de télémétrie de sécurité cardiaque in vivo antérieures et complètent les constatations sur l'activité de BETR-001 au récepteur 5HT-2B, où il agit en tant qu'antagoniste plutôt qu'agoniste. Cela est significatif car l'agonisme au récepteur 5HT-2B est associé à une valvulopathie cardiaque. Ces résultats positifs rapprochent l'entreprise de l'achèvement des études permettant l'IND et du début des essais cliniques.
BetterLife Pharma hat günstige Daten zur kardialen Sicherheit für seinen Arzneimittelkandidaten BETR-001, ein nicht-halluzinogener Derivat von LSD, bekannt gegeben. Das Unternehmen hat GLP-in-vitro-Studien abgeschlossen, die minimale Auswirkungen auf den hERG-Kanal zeigen, der für die Herzfunktion wichtig ist. Die Ergebnisse stimmen mit früheren in-vivo-Studien zur kardialen Sicherheit und ergänzen die Erkenntnisse über die Aktivität von BETR-001 am 5HT-2B-Rezeptor, an dem es als Antagonist und nicht als Agonist wirkt. Dies ist bedeutend, da die Agonismus am 5HT-2B-Rezeptor mit einer kardialen Valvulopathie in Verbindung gebracht wird. Diese positiven Ergebnisse bringen das Unternehmen näher an den Abschluss der IND-erlaubenden Studien und den Beginn klinischer Prüfungen.
- Favorable cardiac safety profile demonstrated in GLP in vitro studies
- BETR-001 shows minimal impact on important hERG channel
- Drug acts as antagonist at 5HT-2B receptor, reducing cardiac valvulopathy risk
- Progress toward completing IND-enabling studies
- None.
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether-a-go-go-related gene (hERG) channel, an important ion channel for cardiac functioning.
Dr. Ahmad Doroudian, CEO of BetterLife, commented, “We are very pleased with these hERG safety data. They are fully in line with our previously conducted in vivo cardiac safety telemetry studies. Furthermore, they complement our previously published findings on BETR-001 activity at the 5HT-2B receptor1. Those studies show that, in contrast to LSD and other psychedelics which exhibit robust agonism at the 5HT-2B receptor, BETR-001 is an antagonist at the 5HT-2B receptor. Agonism at the 5HT-2B receptor is linked to cardiac valvulopathy and therefore, undesirable2. The clean cardiac safety profile of BETR-001 gets us one step closer to completing our full IND-enabling studies and starting our clinical trials, as soon as the studies conclude.”
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
For further information, please visit BetterLife Pharma.
Contact
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Cautionary Note Regarding Forward-Looking Statements
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
___________________________
1 Lewis, et al. Cell Reports 2023
2 Hutcheson, et al. Pharmacol Ther 2011
FAQ
What are the cardiac safety results for BetterLife's BETR-001 (BETRF)?
How does BETR-001's (BETRF) 5HT-2B receptor activity differ from LSD?
What is the next step for BetterLife's BETR-001 (BETRF) development?
